Cargando…

HLA-DRB1*03 as a risk factor for microalbuminuria in same duration of type 1 diabetes: a case control study

BACKGROUND: Increased urinary albumin excretion rate is the earliest clinical manifestation of diabetic nephropathy. The development of microalbuminuria in patients with type 1 diabetes mellitus (T1D) usually begins 5 to 15 years after the onset of diabetes. The rate of progression of diabetic nephr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ražanskaitė-Virbickienė, Dovilė, Danytė, Evalda, Žalinkevičius, Rimantas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815109/
https://www.ncbi.nlm.nih.gov/pubmed/27036319
http://dx.doi.org/10.1186/s12882-016-0252-4
_version_ 1782424538195165184
author Ražanskaitė-Virbickienė, Dovilė
Danytė, Evalda
Žalinkevičius, Rimantas
author_facet Ražanskaitė-Virbickienė, Dovilė
Danytė, Evalda
Žalinkevičius, Rimantas
author_sort Ražanskaitė-Virbickienė, Dovilė
collection PubMed
description BACKGROUND: Increased urinary albumin excretion rate is the earliest clinical manifestation of diabetic nephropathy. The development of microalbuminuria in patients with type 1 diabetes mellitus (T1D) usually begins 5 to 15 years after the onset of diabetes. The rate of progression of diabetic nephropathy varies considerably among patients and not always can be explained solely by glycaemic control. The evidence suggests that genetic susceptibility may play a role in the development of diabetes microvascular complications, besides the presence of such risk factors as hyperglycaemia, hypertension, dyslipidaemia and smoking. The aim of the study was to evaluate a link between known genetic risk factors for type 1 diabetes mellitus (HLA-DR3/DR4) and microalbuminuria among patients with the same durations of diabetes. METHODS: Ninety-nine patients with T1D at the age 18–35 years were recruited for the study. The urine albumin excretion rate was normal when <30 mg/24 h; microalbuminuria 30–300 mg/24 h. Genotypes were investigated in 39 patients with normal albumin excretion rate and duration of diabetes 13.46 ± 3.72 years and in 60 patients with microalbuminuria and duration of diabetes 15.28 ± 4.08 years (p = 0.11). Genetic typing of DR3 and DR4 antigens successfully was performed for 99 subjects. Statistical analysis was performed using SPSS v. 20.0. RESULTS: Genotyping of 99 patients with T1D was performed: no DR3 and DR4 risk alleles were found in 22 (22.22 %) cases, DR3 alleles were present in 47 (47.48 %) cases, DR4 alleles in 25 (25.25 %) cases, and DR3/DR4 alleles in 5 (5.05 %) cases. The highest 24 h albumin excretion rate was found in patients with DRB1 gene expressed DR3 risk alleles group, the lowest - in patients with DRB1 gene with no expression of both DR3 and DR4 antigen. We confirmed the 1.87 (p = 0.021) increased relative risk for microalbuminuria in patients with DR3/DR3 alleles and same duration of diabetes. The distribution of DR3 and DR4 risk alleles was not associated with cardiovascular autonomic neuropathy both in patients with normal albumin excretion rate and microalbuminuria (1.6 vs 2.1; p = 0.21). CONCLUSIONS: The 1.87 (p = 0.021) increased relative risk for microalbuminuria was found in patients with DR3/DR3 alleles and the same duration of diabetes.
format Online
Article
Text
id pubmed-4815109
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48151092016-04-01 HLA-DRB1*03 as a risk factor for microalbuminuria in same duration of type 1 diabetes: a case control study Ražanskaitė-Virbickienė, Dovilė Danytė, Evalda Žalinkevičius, Rimantas BMC Nephrol Research Article BACKGROUND: Increased urinary albumin excretion rate is the earliest clinical manifestation of diabetic nephropathy. The development of microalbuminuria in patients with type 1 diabetes mellitus (T1D) usually begins 5 to 15 years after the onset of diabetes. The rate of progression of diabetic nephropathy varies considerably among patients and not always can be explained solely by glycaemic control. The evidence suggests that genetic susceptibility may play a role in the development of diabetes microvascular complications, besides the presence of such risk factors as hyperglycaemia, hypertension, dyslipidaemia and smoking. The aim of the study was to evaluate a link between known genetic risk factors for type 1 diabetes mellitus (HLA-DR3/DR4) and microalbuminuria among patients with the same durations of diabetes. METHODS: Ninety-nine patients with T1D at the age 18–35 years were recruited for the study. The urine albumin excretion rate was normal when <30 mg/24 h; microalbuminuria 30–300 mg/24 h. Genotypes were investigated in 39 patients with normal albumin excretion rate and duration of diabetes 13.46 ± 3.72 years and in 60 patients with microalbuminuria and duration of diabetes 15.28 ± 4.08 years (p = 0.11). Genetic typing of DR3 and DR4 antigens successfully was performed for 99 subjects. Statistical analysis was performed using SPSS v. 20.0. RESULTS: Genotyping of 99 patients with T1D was performed: no DR3 and DR4 risk alleles were found in 22 (22.22 %) cases, DR3 alleles were present in 47 (47.48 %) cases, DR4 alleles in 25 (25.25 %) cases, and DR3/DR4 alleles in 5 (5.05 %) cases. The highest 24 h albumin excretion rate was found in patients with DRB1 gene expressed DR3 risk alleles group, the lowest - in patients with DRB1 gene with no expression of both DR3 and DR4 antigen. We confirmed the 1.87 (p = 0.021) increased relative risk for microalbuminuria in patients with DR3/DR3 alleles and same duration of diabetes. The distribution of DR3 and DR4 risk alleles was not associated with cardiovascular autonomic neuropathy both in patients with normal albumin excretion rate and microalbuminuria (1.6 vs 2.1; p = 0.21). CONCLUSIONS: The 1.87 (p = 0.021) increased relative risk for microalbuminuria was found in patients with DR3/DR3 alleles and the same duration of diabetes. BioMed Central 2016-03-31 /pmc/articles/PMC4815109/ /pubmed/27036319 http://dx.doi.org/10.1186/s12882-016-0252-4 Text en © Ražanskaitė-Virbickienė et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ražanskaitė-Virbickienė, Dovilė
Danytė, Evalda
Žalinkevičius, Rimantas
HLA-DRB1*03 as a risk factor for microalbuminuria in same duration of type 1 diabetes: a case control study
title HLA-DRB1*03 as a risk factor for microalbuminuria in same duration of type 1 diabetes: a case control study
title_full HLA-DRB1*03 as a risk factor for microalbuminuria in same duration of type 1 diabetes: a case control study
title_fullStr HLA-DRB1*03 as a risk factor for microalbuminuria in same duration of type 1 diabetes: a case control study
title_full_unstemmed HLA-DRB1*03 as a risk factor for microalbuminuria in same duration of type 1 diabetes: a case control study
title_short HLA-DRB1*03 as a risk factor for microalbuminuria in same duration of type 1 diabetes: a case control study
title_sort hla-drb1*03 as a risk factor for microalbuminuria in same duration of type 1 diabetes: a case control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815109/
https://www.ncbi.nlm.nih.gov/pubmed/27036319
http://dx.doi.org/10.1186/s12882-016-0252-4
work_keys_str_mv AT razanskaitevirbickienedovile hladrb103asariskfactorformicroalbuminuriainsamedurationoftype1diabetesacasecontrolstudy
AT danyteevalda hladrb103asariskfactorformicroalbuminuriainsamedurationoftype1diabetesacasecontrolstudy
AT zalinkeviciusrimantas hladrb103asariskfactorformicroalbuminuriainsamedurationoftype1diabetesacasecontrolstudy